Eur J Pharmacol 469:195200 Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
About 4% of Americans are taking some form of GLP-1 drug for weight-loss or to treat type 2 diabetes, a 600% increase in usage from six years ago, according to May data from FAIR Health
[DOI] [PubMed] [Google Scholar] 18.Dickinson JK, Guzman SJ, Maryniuk MD, et al
Sugar and ultraprocessed food combine a general lack of nutrition with the risk of blood sugar spikes and crashes, which can put those on diabetes medications at higher risk and cause nausea, fatigue, and cravings in general
We showed that the antibody Fab fragment (Fab 3F52) blocked the GLP-1 binding site of the ECD directly and thereby acts as a competitive antagonist of native GLP-1